Geneva, Switzerland, October 17, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled new data further documenting the presence of W-ENV in cohorts of post-COVID patients at the18th Symposium of the International Society of Neuro Virology (ISNV) held on October 11-14, 2022.
https://geneuro.com/data/news/GeNeuro-ISNV-presentation-ENG-Oct.-17-2022.pdf